Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study

被引：0
|
作者：
Mauro, Michael [1 ]
Hochhaus, Andreas [2 ]
Hughes, Timothy [3 ,4 ]
Rea, Delphine [5 ]
Boquimpani, Carla [6 ]
Minami, Yosuke [7 ]
Apperley, Jane [8 ]
Garcia-Gutierrez, Valentin [9 ]
Kapoor, Shruti [10 ]
Espurz, Noemi [11 ]
Dhamal, Vishal [12 ]
Cortes, Jorge [13 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Univ Klinikum Jena, Jena, Germany
[3] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia
[4] Univ Adelaide, Adelaide, SA, Australia
[5] Hop St Louis, Paris, France
[6] State Inst Hematol Arthur Siquiera Cavalcanti, HEMORIO, Rio De Janeiro, Brazil
[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[8] Ctr Haematol Imperial Coll London, London, England
[9] Hosp Univ Ramon & Cajal IRYCIS, Serv Hematol, Madrid, Spain
[10] Novartis Pharmaceut, E Hanover, NJ USA
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Healthcare Private Ltd, Hyderabad, India
[13] Georgia Canc Ctr, Augusta, GA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CML; asciminib; TKI; ASCEMBL; phase III;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-398
引用
收藏
页码：S340 / S340
页数：1
相关论文
共 50 条
  • [21] An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors
    Garcia-Gutierrez, Valentin
    Carlos Hernandez-Boluda, Juan
    EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (06) : 477 - 484
  • [22] Asciminib Once-Daily (QD) Dosing Demonstrates Comparable Tolerability and Efficacy to Twice-Daily (BID) Dosing: Updated Results From the AIM4CML Study in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With Prior Tyrosine Kinase Inhibitor (TKI) Treatment
    Levy, Moshe
    Andorsky, David
    Issa, Ghayas
    Broun, Edward
    Essell, James
    Abboud, Camille
    Damon, Andrea
    Starinsky, Amy
    Sadek, Islam
    Parveen, Naseema
    Mauro, Michael
    Deininger, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S367 - S367
  • [23] Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib
    Perez-Lamas, Lucia
    Diaz, Adrian Segura
    Castera, Elvira Mora
    Soto, Marta Hidalgo
    Coll, Antonio Paz
    de las Heras, Natalia
    Cortes, Montse
    Tenza, Patricia Velez
    Pacho, Magdalena Sierra
    Magan, Alicia Senin
    Angona, Anna
    Cervero, Carlos
    de Paz, Raquel
    Cuenca, Araceli Salamanca
    Santaliestra, Marta
    Marin, Javier Lopez
    Casado, Luis Felipe
    Garcia-Gutierrez, Valentin
    ANNALS OF HEMATOLOGY, 2024, 103 (11) : 4537 - 4544
  • [24] ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results
    Cortes, Jorge E.
    Andorsky, David J.
    Issa, Ghayas C.
    Hughes, Timothy P.
    Hochhaus, Andreas
    Takahashi, Naoto
    Bombaci, Felice
    Wang, Jianxiang
    Kim, Dong-Wook
    Kim, Dennis Dong Hwan
    Mayer, Jiri
    Goh, Yeow-Tee
    le Coutre, Philipp
    Kapoor, Shruti
    McCulloch, Tracey
    Malek, Kamel
    Yau, Lillian
    Ifrah, Sophie
    Larson, Richard A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S369 - S370
  • [25] Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
    Falchi, Lorenzo
    Kantarjian, Hagop M.
    Wang, Xuemei
    Verma, Dushyant
    Quintas-Cardama, Alfonso
    O'Brien, Susan
    Jabbour, Elias J.
    Ravandi-Kashani, Farhad
    Borthakur, Gautam
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Burger, Jan A.
    Luthra, Raja
    Cortes, Jorge E.
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (12) : 1024 - 1029
  • [26] ASC4START: A Phase 3b, Open-Label, Randomized Study of Asciminib vs Nilotinib in Patients With Newly Diagnosed Ph plus Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
    Strickland, Stephen
    Andorsky, David
    Bruemmendorf, Tim
    Saussele, Susanne
    Mahon, Francois-Xavier
    Pilipovic, Virginia
    Zhang, Yifan
    Schuld, Peter
    Hochhaus, Andreas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S349 - S350
  • [27] Combination of Asciminib plus Nilotinib or Asciminib plus Dasatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results
    DeAngelo, Daniel J.
    Mauro, Michael J.
    Kim, Dong-Wook
    Cortes, Jorge
    Rea, Delphine
    Hughes, Timothy P.
    Minami, Hironobu
    Breccia, Massimo
    Talpaz, Moshe
    Hochhaus, Andreas
    Goh, Yeow Tee
    Le Coutre, Philipp D.
    Sondhi, Manu
    Mishra, Kaushal
    Hourcade-Potelleret, Florence
    Vanasse, Gary
    Aimone, Paola
    Lang, Fabian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S290 - S291
  • [28] Phase 2 study of dasatinib in Chinese patients with chronic myeloid leukemia (CML) in chronic phase (CP) or advanced phase who are resistant to or intolerant of imatinib (IM)
    Wang, Jianxiang
    Huang, Xiaojun
    Hu, Jianda
    Li, Jianyong
    Jin, Jie
    Meng, Fanyi
    Shen, Zhixiang
    Liu, Ting
    Wu, Depei
    Wang, Jianmin
    LEUKEMIA & LYMPHOMA, 2013, 54 : 3 - +
  • [29] ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI)
    Sasaki, Koji
    Mauro, Michael J.
    Levy, Moshe Y.
    Atallah, Ehab L.
    Koller, Paul
    Maegawa, Rodrigo
    Damon, Andrea
    Kumar, Julie
    Khan, Mahmudul
    Cortes, Jorge E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S299 - S299
  • [30] Mild Clinical Course of COVID-19 Infection in Chronic Myeloid Leukemia (CML) Patients Receiving Tyrosine Kinase Inhibitors (TKIs) without Interruption
    Demeter, Judit
    Weisinger, Julia
    Nagy, Zsolt
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2021, 13
12345